HKGEquity · Weekly research terminal

9637

Alebund Pharmaceuticals (Jiangsu) Limited

HK Healthcare Drug Manufacturers - General

Latest week
7 Aug 2026
Weekly close
32.68 HKD
Fair value
29.67 HKD
Next-week expectancy
Negative 43.14%
SM Sharemaestro
Institutional Weekly Chart Pack Completed-week market evidence · Maximum 156 weeks

HKG · Equity · Hong Kong

9637

Alebund Pharmaceuticals (Jiangsu) Limited

Healthcare Drug Manufacturers - General

Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong. Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307. Alebund Pharmaceuticals (Jiangsu) Limited was founded in 2018 and is headquartered in Yangzhou, China.

Last updated
7 Aug 2026
Exchange
Hong Kong Stock Exchange · HKG
Sector
Healthcare
Industry
Drug Manufacturers - General
Currency
HKD
Market capitalisation
9,828,526,080
Fair value reference
29.67
Next-week expectancy
Negative · 43.14%

Over the latest 12 completed weeks ending 2026-08-07, 9637 rose 7.93%, moving from 30.28 to 32.68. The latest weekly close is above Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 6 weeks. Market Dynamics is 0.00 on the latest week. Next-week expectancy is negative at 43.14% based on similar historical setup states.

Week Ending
7 Aug 2026
Latest Close
32.68
12-Week Change
7.93%
Trend Signal
Inactive
Next-Week Expectancy
Negative 43.14%
Signal Weeks
0 of 6

Weekly Price

Weekly Close Trend Line Fair Value Activity Lines

Chart Panels

Choose up to 5 panels. Drag panel headers to reorder.

Chart Summary

Key Points

Week Ending
7 Aug 2026
Latest Close
32.68
12-Week Change
7.93%
Trend Signal
Inactive
Next-Week Expectancy
Negative 43.14%
Signal Weeks
0 of 6
Vs Fair Value
Above
Market Dynamics
0.00

Over the latest 12 completed weeks ending 2026-08-07, 9637 rose 7.93%, moving from 30.28 to 32.68. The latest weekly close is above Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 6 weeks. Market Dynamics is 0.00 on the latest week. Next-week expectancy is negative at 43.14% based on similar historical setup states.

Industry Peers

Hong Kong equities in Drug Manufacturers - General

Stock Exchange Week Open High Low Close Change
2630 Vigonvita Life Sciences Co., Ltd. HKG 7 Aug 2026 96.00 118.80 91.30 116.80 21.67%
1093 CSPC Pharmaceutical Group Limited HKG 7 Aug 2026 8.52 8.76 8.21 8.69 2.00%
1666 Tong Ren Tang Technologies Co. Ltd. HKG 7 Aug 2026 3.50 3.57 3.31 3.37 -3.86%
7630 IMPACT THERAP-B HKG 7 Aug 2026 13.23 13.23 11.42 12.51 -5.44%
1643 Modern Chinese Medicine Group Co., Ltd. HKG 7 Aug 2026 1.10 1.10 0.85 0.85 -23.18%
6915 JIANGXI BIO HKG 7 Aug 2026 16.80 16.80 9.55 9.63 -42.68%

Next-week expectancy

Next-week expectancy is a short-term historical read. It compares the latest completed-week setup with broadly similar past setups and asks whether the following week tended to close higher or lower.

It is not a trend call, a price target, or a guarantee. A positive read can appear while price is below trend or activity pressure is weak, because it is measuring short-term follow-through odds for the current setup state.

Use it as one context layer beside Trend Line, Relative Strength, Market Dynamics, Fair Value, and the visible price structure.

Evidence context